Stimcell Energetics Inc 10-Q for FY2024 Q3
Stimcell Energetics Inc. (STME)
About this 10-Q
Stimcell Energetics Inc filed this 10-Q on April 15, 2024, covering the quarter ended February 29, 2024 (FY2024 Q3).
Headline figures
Quarter ended February 29, 2024, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $0
- compared with $222 a year earlier
- Net income
- $119.97K
- compared with a net loss of $118.16K a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
ACT OF 1934
For the quarterly period ended
or
ACT OF 1934
Commission File Number:
(Exact name of registrant as specified in its charter)
| ||
(State or other jurisdiction of |
| (I.R.S. Employer |
incorporation or organization) |
| Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip code) |
(
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ |
| Accelerated filer ☐ |
| Smaller Reporting Company | |
|
| Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
i
Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.) Yes
The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of April 15, 2024, was
ii
CONTENTS
iii
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
The accompanying unaudited condensed consolidated financial statements of Cell MedX Corp. as at February 29, 2024, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ deficit in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.
Operating results for the three- and nine-month periods ended February 29, 2024, are not necessarily indicative of the results that can be expected for the year ending May 31, 2024.
As used in this Quarterly Report, the terms “we,” “us,” “our,” “Cell MedX,” and the “Company” mean Cell MedX Corp. and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.
1
CELL MEDX CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(EXPRESSED IN US DOLLARS)
(UNAUDITED)
February 29, 2024 |
| May 31, 2023 | |||
ASSETS |
|
|
| ||
|
|
|
| ||
Current assets |
|
|
| ||
Cash | $ |
| $ | ||
Other current assets |
|
|
| ||
Total assets | $ |
| $ | ||
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
Liabilities |
|
|
|
|
|
Accounts payable | $ |
| $ | ||
Accrued liabilities |
|
|
| ||
Due to related parties |
|
|
| ||
Notes and advances due to related parties |
|
|
| ||
Notes and advances payable |
|
|
| ||
Total liabilities |
|
|
| ||
|
|
|
|
|
|
STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
Common stock, $ February 29, 2024, and May 31, 2023, respectively |
|
|
| ||
Additional paid-in capital |
|
|
| ||
Obligation to issue shares |
|
|
| ||
Reserves |
|
|
| ||
Accumulated deficit |
| ( |
|
| ( |
Accumulated other comprehensive income |
|
|
| ||
Total stockholders’ deficit |
| ( |
|
| ( |
Total liabilities and stockholders’ deficit | $ |
| $ | ||
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-1
CELL MEDX CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(EXPRESSED IN US DOLLARS)
(UNAUDITED)
|
| Three Months Ended |
| Nine Months Ended | ||||||||
| February 29, 2024 |
| February 28, 2023 |
| February 29, 2024 |
| February 28, 2023 | |||||
|
|
|
|
|
|
|
|
| ||||
Revenue |
|
|
|
|
|
|
|
| ||||
Sales |
| $ |
| $ |
| $ |
| $ | ||||
Cost of goods sold |
|
|
|
| ( |
|
|
|
| |||
Gross margin |
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Consulting fees |
|
|
|
|
|
|
|
| ||||
General and administrative expenses |
|
|
|
|
|
|
|
| ||||
Research and development costs |
|
| ( |
|
|
|
| ( |
|
| ||
Total operating expenses |
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Other items |
|
|
|
|
|
|
|
|
|
|
|
|
Forgiveness of debt |
|
|
|
|
|
|
|
| ||||
Interest |
|
| ( |
|
| ( |
|
| ( |
|
| ( |
Net income (loss) |
|
|
|
| ( |
|
| ( |
|
| ( | |
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation |
|
| ( |
|
|
|
| ( |
|
| ||
Comprehensive income (loss) |
| $ |
| $ | ( |
| $ | ( |
| $ | ( | |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per common share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
| $ |
| $ | ( |
| $ | ( |
| $ | ( | |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
|
|
|
|
|
| ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-2
CELL MEDX CORP.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT
(EXPRESSED IN US DOLLARS)
(UNAUDITED)
| Common Stock |
|
|
|
|
|
| ||||||||
Shares | Amount | Additional Paid-in Capital | Obligation to Issue Shares | Reserves | Deficit Accumulated | Accumulated Other Comprehensive Income (Loss) | Total | ||||||||
|
|
|
|
|
|
|
|
| |||||||
Balance - May 31, 2022 | $ | $ | $ | $ | $ | ( | $ | ( | $ | ( | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period ended Aug 31, 2022 |
|
|
|
|
| ( |
|
| ( | ||||||
Translation to reporting currency |
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - Aug 31, 2022 |
|
|
|
|
| ( |
|
| ( | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period ended Nov 30, 2022 |
|
|
|
|
| ( |
|
| ( | ||||||
Translation to reporting currency |
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - Nov 30, 2022 |
|
|
|
|
| ( |
|
| ( | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period ended Feb 28, 2023 |
|
|
|
|
| ( |
|
| ( | ||||||
Translation to reporting Currency |
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - Feb 28, 2023 | $ | $ |
| $ | $ | ( | $ | $ | ( | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - May 31, 2023 | $ | $ |
| $ | $ | ( | $ | $ | ( | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period ended Aug 31, 2023 |
|
|
|
|
| ( |
|
| ( | ||||||
Translation to reporting currency |
|
|
|
|
|
| ( |
| ( | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - Aug 31, 2023 |
|
|
|
|
| ( |
|
| ( | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period ended Nov 30, 2023 |
|
|
|
|
| ( |
|
| ( | ||||||
Translation to reporting currency |
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - Nov 30, 2023 |
|
|
|
|
| ( |
|
| ( | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for debt |
|
|
|
|
|
|
| ||||||||
Obligation to issue shares |
|
|
|
|
|
|
| ||||||||
Net income for the period ended Feb 29, 2024 |
|
|
|
|
|
|
| ||||||||
Translation to reporting currency |
|
|
|
|
|
| ( |
| ( | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - Feb 29, 2024 | $ | $ | $ | $ | $ | ( | $ | $ | ( | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-1
CELL MEDX CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(EXPRESSED IN US DOLLARS)
(UNAUDITED)
| Nine Months Ended | ||||
February 29, 2024 |
| February 28, 2023 | |||
|
|
|
| ||
Cash flows used in operating activities |
|
|
| ||
Net loss | $ | ( |
| $ | ( |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
|
|
Accrued interest on notes payable |
|
|
| ||
Accrued interest on vendor payables |
|
|
| ||
Gain on forgiveness of debt |
| ( |
|
| |
Unrealized foreign exchange |
| ( |
|
| |
Changes in operating assets and liabilities |
|
|
|
|
|
Other current assets |
|
|
| ||
Accounts payable |
|
|
| ( | |
Accrued liabilities |
| ( |
|
| ( |
Due to related parties |
|
|
| ||
Net cash flows used in operating activities |
| ( |
|
| ( |
|
|
|
|
|
|
Cash flows provided by financing activities |
|
|
|
|
|
Proceeds from notes due to related parties |
|
|
| ||
Proceeds from subscription to shares |
|
|
| ||
Net cash provided by financing activities |
|
|
| ||
|
|
|
|
|
|
Effects of foreign currency exchange on cash |
|
|
| ( | |
Decrease in cash |
| ( |
|
| ( |
Cash, beginning |
|
|
| ||
Cash, ending | $ |
| $ | ||
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-1
CELL MEDX CORP.
NOTES TO THE CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
FEBRUARY 29, 2024
(Unaudited)
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS
Cell MedX Corp. (Cell MedX, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness.
Unaudited Interim Financial Statements
The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2023, included in the Company’s Annual Report on Form 10-K, filed with the SEC on September 1, 2023. The interim unaudited condensed consolidated financial statements for the three and nine months ended February 29, 2024, should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and nine months ended February 29, 2024, are not necessarily indicative of the results that may be expected for the year ending May 31, 2024.
Going concern
The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of February 29, 2024, the Company has not achieved profitable operations and has accumulated a deficit of $
NOTE 2 - RELATED PARTY TRANSACTIONS
Amounts due to related parties, other than advances and notes payable to related parties (Note 3) at February 29, 2024, and at May 31, 2023:
February 29, 2024 | May 31, 2023 | |||
Due to the Chief Executive Officer (“CEO”) and President | $ | $ | ||
Due to the former Chief Executive Officer(3) |
|
| ||
Due to the Chief Financial Officer (“CFO”) |
|
| ||
Due from the former Vice President (“VP”), Technology and Operations |
|
| ( | |
Due to a company controlled by the director and former Chief Operating Officer (“COO”)(2) |
|
| ||
Due to a company controlled by the former COO and a major shareholder |
|
| ||
Due to Live Current Media, Inc. (“LIVC”)(1) |
|
| ||
Due to a significant shareholder(2, 3) |
|
| ||
Due to related parties | $ | $ | ||
(1)LIVC is related to the Company through Mr. David Jeffs, significant shareholder of LIVC, who is a close relative of the Company’s significant shareholder, Mr. Richard Jeffs.
(2)During the nine-month period ended February 29, 2024, a company controlled by the former COO and current director assigned a total of $682,590 owed to it in separate transactions; of this amount a total of $425,590 were transferred to the Company’s related parties.
F-2
(3)During the nine-month period ended February 29, 2024, the Company’s former CEO assigned a total of $76,500 owed to him to Mr. Vahabzadeh a significant shareholder of the Company.
The amounts due to related parties are unsecured, due on demand and bear no interest.
During the nine-month periods ended February 29, 2024 and February 28, 2023, the Company had the following transactions with related parties:
February 29, 2024 |
| February 28, 2023 | |||
Management fees incurred to the CEO and President | $ |
| $ | ||
Management fees incurred to the former CEO |
|
|
| ||
Consulting fees incurred to the CFO(1) |
|
|
| ||
Consulting fees incurred to the former VP, Technology and Operations |
|
|
| ||
Consulting fees incurred to the company controlled by a director and former COO |
|
|
| ||
Royalty incurred to LIVC |
|
|
| ||
Royalty incurred to a company controlled by a director and former COO and Mr. Richard Jeffs |
|
|
| ||
Total transactions with related parties | $ |
| $ | ||
(1)During the nine-month period ended February 29, 2024, the services provided by the CFO were recorded as part of consulting fees. In the prior period, the services provided by the CFO were recorded as part of management fees.
NOTE 3 - NOTES AND ADVANCES DUE TO RELATED PARTIES
The tables below summarize the loans and advances due and payable to related parties as at February 29, 2024 and May 31, 2023:
As at February 29, 2024 | ||||||||
Principal Outstanding | Interest Rate per Annum |
| Accrued Interest | Total Book Value | ||||
$ | Related party loans payable (1) | $ | $ | |||||
| Related party loans payable (1) |
|
| |||||
| Advances(2) |
| - |
| ||||
$ |
|
| $ | $ | ||||
| ||||||||
As at May 31, 2023 | ||||||||
Principal Outstanding | Interest Rate per Annum |
| Accrued Interest | Total Book Value | ||||
$ | Related party loans payable (1) | $ | $ | |||||
| Related party loans payable (1) |
|
| |||||
| Advances(2) |
| - |
| ||||
$ |
|
| $ | $ | ||||
(1) Related Party Loans Payable
As at February 29, 2024, the Company owed a total of $
As at February 29, 2024, the Company owed a total of $
F-3
Notes payable with Mr. Richard Jeffs
As at February 29, 2024, the Company owed a total of $
On December 7, 2023, Mr. Richard Jeffs notified the Company that he had reassigned the notes payable the Company issued to him totaling $411,000 and CAD$26,800 to Mr. David Jeffs. The total amount reassigned including interest was $477,420. On assignment, the terms of the notes payable did not change, remaining payable on demand, accumulating interest at 6% annual interest compounded monthly.
On December 18, 2023, the Company and Mr. Richard Jeffs entered into a debt settlement agreement, whereas Mr. Richard Jeffs agreed to settle a total of $
Notes payable with Mr. David Jeffs
As at February 29, 2024, the Company owed a total of $
On December 7, 2023, Mr. David Jeffs acquired, through reassignment of debt by Mr. Richard Jeffs, a total of $477,420 in notes payable including interest accrued thereon. On assignment, the terms of the notes payable did not change, remaining payable on demand, accumulating interest at 6% annual interest compounded monthly.
On December 14, 2023, Mr. David Jeffs notified the Company that he had reassigned a total of $105,000 to two members of his family.
On December 18, 2023, the Company and Mr. David Jeffs entered into a debt settlement agreement, whereas Mr. David Jeffs agreed to settle a total of $
As at February 29, 2024, the Company owed a total of $
Notes payable with Mr. Amir Vahabzadeh
As at February 29, 2024, the Company owed a total of $
F-4
On December 18, 2023, the Company and Mr. Vahabzadeh entered into a debt settlement agreement, whereas Mr. Vahabzadeh agreed to settle a total of $
During the nine-month period ended February 29, 2024, the Company recorded $
Notes payable with Mrs. Susan Jeffs
As at February 29, 2024, the Company had no amounts due under the loan agreement with Mrs. Susan Jeffs, wife of Mr. Richard Jeffs and mother of Mr. David Jeffs (May 31, 2023 - $
During the nine-month period ended February 29, 2024, the Company recorded $
Notes payable with Mr. Brad Hargreaves
As at February 29, 2024, the Company owed $
Notes payable with a significant shareholder
During the nine-month period ended February 29, 2024, a holder of
As at February 29, 2024, the Company owed $
(2) Advances Payable
As at February 29, 2024, the Company owed a total of $
On December 18, 2023, the Company entered into separate debt settlement agreements with Da Costa Management Corp (“DCM”), a company owned by John da Costa, a director of the Company and former COO, and Mr. David Jeffs, whereas DCM and Mr. David Jeffs agreed to settle a total of $
F-5
NOTE 4 - NOTES AND ADVANCES PAYABLE
As at February 29, 2024 | ||||||||
Principal Outstanding | Interest Rate per Annum |
| Accrued Interest | Total Book Value | ||||
$ | Loans payable(1) | $ | $ | |||||
| Loans payable(2) |
|
| |||||
$ |
|
| $ | $ | ||||
As at May 31, 2023 | ||||||||
Principal Outstanding | Interest Rate per Annum |
| Accrued Interest | Total Book Value | ||||
$ | Loans payable | $ | $ | |||||
| Loans payable |
|
| |||||
$ |
|
| $ | $ | ||||
(1)During the nine-month period ended February 29, 2024, one of the Company’s note holders sold its debt to Mr. Vahabzadeh, a director and significant shareholder. The total amount of the notes payable on the day of the transaction was $118,587. Upon the sale, the terms of the loans did not change and continued to accumulate 6% annual interest compounded monthly, payable on demand, and being unsecured. Mr. Vahabzadeh converted the principal owed under these loans on December 18, 2023, and forgave the interest accumulate as of that date (Note 3).
(2)During the nine-month period ended February 29, 2024, a holder of 10% notes payable (“Mr. Ahdoot”) acquired, in a private transaction, $167,000 in debt the Company owed to an entity controlled by the former COO and current director of the Company. Mr. Ahdoot agreed to convert the $167,000 debt into 23,857,142 shares of the Company’s common stock at $0.007 per share, which resulted in Mr. Ahdoot becoming a significant shareholder of the Company. Therefore, as at February 29, 2024, the balance due to Mr. Ahdoot under the notes payable has been included in the notes and advances due to related parties (Note 3).
During the nine-month period ended February 29, 2024, the Company recorded $
NOTE 5 - DEBT CONVERSION AND FORGIVENESS OF DEBT
On December 18, 2023, the Company entered into agreements to settle debt in the aggregate amount of $
The following table shows the details of Debt Settlement.
| Amount converted | Shares issued on conversion | |
Debt converted with the director and CEO | $ | ||
Debt converted with a company controlled by director and former COO |
| ||
Debt converted with Mr. David Jeffs |
| ||
Debt converted with Mr. Vahabzadeh |
| ||
Debt converted with the spouse of Mr. Vahabzadeh |
| ||
Debt converted with family members of Mr. David Jeffs |
| ||
Debt converted with Susan Jeffs |
| ||
Debt converted with Richard Jeffs |
| ||
Debt converted with other debt holders |
| ||
Total | $ | ||
F-6
Simultaneously with the conversion of debt into shares, certain debt holders agreed to waive the accrued interest on the principal amount due under the notes payable. Furthermore, the Company discharged outstanding debts to specific vendors due to the balances exceeding the statute of limitations. The following table provides further details on the gain recognized as a result of forgiveness of debt:
| Amount forgiven | |
Accrued interest due to Mr. Richard Jeffs | $ | |
Accrued interest due to Mr. David Jeffs |
| |
Accrued interest due to Mrs. Susan Jeffs |
| |
Accrued interest due to Mr. Vahabzadeh |
| |
Sub-total accrued interest recognized as gain on forgiveness of debt |
| 100,186 |
Vendor payables that have exceeded the statute of limitations |
| |
Total | $ | |
NOTE 6 - OTHER CURRENT ASSETS
As at February 29, 2024, other current assets consisted of $
NOTE 7 - REVENUE
During the three- and nine-month periods ended February 28, 2023, the Company’s revenue consisted of monthly subscriptions to eBalance® microcurrent treatments. As at May 31, 2023, the Company had stopped all its commercial activity due to loss of licenses issued previously by Health Canada, therefore the Company had no revenue for the three- and nine-month periods ended February 29, 2024.
Following are the details of revenue and associated costs:
| Three months ended | Nine months ended | ||||||
| February 29, 2024 | February 28, 2023 | February 29, 2024 | February 28, 2023 | ||||
Monthly subscriptions | $ | - | $ | $ | - | $ | ||
Sales of eBalance® devices |
| - |
|
| - |
| ||
Cost of eBalance® devices and services |
| - |
|
| - |
| ( | |
Royalty payable |
| - |
| ( |
| - |
| ( |
Gross margin | $ | - | $ | $ | - | $ | ||
NOTE 8 - SHARE CAPITAL
On December 18, 2023, the Company issued an aggregate of
As at February 29, 2024, the Company did not have any options or warrants issued and exercisable.
NOTE 9 - SUBSEQUENT EVENTS
On March 12, 2024, the Company closed a private placement offering (the “Offering”) by issuing
Mr. Vahabzadeh and his spouse participated in the Offering acquiring a total of 1,000,000 Units for $30,000 (Note 2).
F-7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion of the Company’s financial condition and results of operations should be read in conjunction with the Company’s unaudited condensed consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the “Risk Factors” in Part II, Item 1A of this Quarterly Report.
The discussion provided in this Quarterly Report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended May 31, 2023, filed with the United States Securities and Exchange Commission (the “SEC”) on September 1, 2023.
Overview
The Company was incorporated under the laws of the State of Nevada on March 19, 2010. On April 26, 2016, the Company formed a wholly owned subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia.
Cell MedX is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health, anti-aging, pain relief, wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, insulin resistance, high blood pressure, neuropathy and kidney function. The Subsidiary is engaged in the development and manufacturing of therapeutic devices based on our proprietary eBalance® Technology, which harnesses the power of microcurrents and their effects on the human body.
Recent Corporate Developments
Change in Management
On December 12, 2023, Mr. Dwayne Yaretz resigned as Chief Executive Officer (“CEO”) of the Company and Mr. Brad Hargreaves resigned as VP of Technology and Operations. Mr. David Jeffs was appointed as the new CEO of the Company. Mr. Jeffs was also appointed to the Company’s board of directors, together with Mr. Amir Vahabzadeh.
On March 6, 2024, the Company filed a definitive Schedule 14C information statement (the “Information Statement”), disclosing written execution of consents by the stockholders of the Company holding 66.0% of the outstanding shares of the Company’s common stock to elect Mr. David Jeffs, Dr. George Adams, Mr. Joao (John) da Costa, and Mr. Amir Vahabzadeh as directors of the Company, which election became effective on or about April 1, 2024,
As of April 1, 2024, Mr. Dwayne Yaretz, Mr. Brad Hargreaves, and Ms. Yanika Silina have ceased to be directors of the Company. Ms. Silina continues to hold positions of the CFO, Secretary, and Treasurer of the Company.
Conversion of Debt to Shares
On December 18, 2023, the Company entered into agreements to settle debt in the aggregate amount of $1,622,693 for shares of the Company’s common stock at a price of $0.007 per share for an aggregate of 231,813,310 shares of common stock (the “Debt Settlement”). The Debt Settlement resulted in a change in control of the Company. As part of the Debt Settlement, Mr. David Jeffs acquired 73,959,726 shares of the Company’s common stock, while family members of Mr. Jeffs acquired an additional 43,819,083 shares of common stock. Mr. Amir Vahabzadeh acquired 61,775,148 shares of common stock, while Mr. Vahabzadeh’s spouse acquired an additional 23,676,239 shares of common stock.
The shares of common stock issued as part of the Debt Settlement were not registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and were issued pursuant to exemptions from the registration requirements provided by Regulation S of the U.S. Securities Act and Rule 506(b) of Regulation D of the U.S. Securities Act.
2
Private Placement Financing
On March 12, 2024, Company closed a private placement offering (the “Offering”) by issuing 2,500,000 units (each a “Unit”) at a price of $0.03 per Unit for gross proceeds of $75,000. Each Unit sold under the Offering consisted of one share in the common stock of the Company and one share purchase warrant (the “Warrant”) expiring on March 12, 2026. Each Warrant is exercisable for one additional share of the Company’s common stock at a price of $0.04 per share on or before September 12, 2024, and at a price of $0.05 per share for the remaining life of the Warrant.
Units issued to non-U.S. persons were issued pursuant to the provisions of Regulation S of the United States Securities Act of 1933, as amended (the “Act”) on the basis that the subscribers are not residents of the United States, are otherwise not “U.S. persons” as that term is defined in Rule 902(k) of Regulation S of the Act and were not in the United States. Units issued to U.S. persons were issued pursuant to the provisions of Rule 506(b) of Regulation D of the Act on the basis that the subscribers are “accredited investors” as that term is defined under Regulation D of the Act.
Mr. Vahabzadeh and his spouse participated in the Offering acquiring a total of 1,000,000 Units for $30,000.
Amendments to Articles of Incorporation
On April 1, 2024, the Company amended its articles of incorporation to increase the authorized capital of the Company from 300,000,000 shares of common stock, par value $0.001 (the “Common Stock”) to 7,500,000,000 shares of Common Stock (the “Increase in Authorized Capital”).
The Increase in Authorized Capital was approved by written consent of stockholders holding an aggregate of 194,627,681 shares of Common Stock, being equal to 66.0% of the number of shares of Common Stock outstanding on the record date for determining stockholders entitled to vote on the Increase in Authorized Capital.
Results of Operations for the Three and Nine Months ended February 29, 2024 and February 28, 2023
Operating results for the three- and nine-month periods ended February 29, 2024 and February 28, 2023, and the changes in the operating results between those periods are summarized in the table below.
| Three Months ended | Percentage Increase/ (Decrease) | Nine Months ended | Percentage Increase/ (Decrease) | |||||||
February 29, 2024 | February 28, 2023 | February 29, 2024 | February 28, 2023 | ||||||||
Sales | $ | - | $ | 222 | (100.0)% | $ | - | $ | 2,688 | (100.0)% | |
Cost of goods |
| - |
| 489 | (100.0)% |
| - |
| (1,734) | (100.0)% | |
Gross margin |
| - |
| 711 | (100.0)% |
| - |
| 954 | (100.0)% | |
Operating expenses |
|
|
|
|
|
|
|
|
|
| |
Consulting fees |
| 35,325 |
| 14,274 | 147.5% |
| 94,796 |
| 61,206 | 54.9% | |
General and administrative expenses |
| 43,534 |
| 48,723 | (10.7)% |
| 77,072 |
| 233,837 | (67.0)% | |
Research and development costs |
| (21,084) |
| 43,546 | (148.4)% |
| (20,477) |
| 88,796 | (123.1)% | |
Total operating expenses |
| 57,775 |
| 106,543 | (45.8)% |
| 151,391 |
| 383,839 | (60.6)% | |
Gain on forgiveness of debt |
| (187,517) |
| - | n/a |
| (187,517) |
| - | n/a | |
Interest |
| 9,771 |
| 12,329 | (20.7)% |
| 53,655 |
| 32,774 | 63.7% | |
Net (income) loss | $ | (119,971) | $ | 118,161 | (201.5)% | $ | 17,529 | $ | 415,659 | (95.8)% | |
Revenues
During the three-month period ended February 29, 2024, the Company did not generate any revenue, as compared to $222 received from monthly recurring revenue associated with the eBalance® treatment packages in the period ending February 28, 2023. The cost attributed to this revenue was $298, and included $3 in royalties accrued on the sales. During the three-month period ended February 28, 2023, the Company reclassified a total of $787 previously recorded as cost of goods sold to general and operating expenses, which resulted in recapture of the cost of goods sold of $489.
During the nine-month period ended February 29, 2024, the Company did not generate any revenue, as compared to $1,138 in revenue from sales of eBalance® devices and $1,550 received from monthly recurring revenue associated with the eBalance® treatment packages in the period ending February 28, 2023. The cost attributed to this revenue was $1,734, and included $323 in royalties accrued on the sales.
3
As of the date of this Quarterly Report on Form 10-Q, revenue-generating activities associated with sales of eBalance® Home and Pro Systems, as well as monthly recurring revenue from the online sales of eBalance® treatment packages continue to be suspended as a result of the cancellation of Health Canada Class II Medical Device licenses for the eBalance® Pro System, and eBalance® Home System.
Operating Expenses
During the three-month period ended February 29, 2024, operating expenses decreased by 45.8% from $106,543 incurred during the three months ended February 28, 2023, to $57,775 incurred during the three months ended February 29, 2024. The largest change was associated with a decrease in research and development fees, which decreased by $64,630, or 148.4%, from $43,546 incurred during the three-month period ended February 28, 2023, to a recapture of $21,084 recognized during the three-month period ended February 29, 2024. The lower research and development fees during the three-month period ended February 29, 2024, were associated with the Company’s decision to suspend further development of the eBalance® devices due to lack of funding and unfavorable financial position, as well as reversal of certain fees that were billed during the Fiscal 2023, for which the services were not provided.
General and administrative fees (the “G&A fees”) decreased by $5,189, from $48,723 incurred during the three months ended February 28, 2023, to $43,534 incurred during the three months ended February 29, 2024. Management fees, which are included in G&A fees, consisted of $15,000 accrued as payable to our CEO for the period ended February 29, 2024, and $15,000 accrued as payable to our former CEO for the period ended February 28, 2023; the management fees decreased by $7,500, as in Fiscal 2024 the fees paid to our CFO have been included as part of consulting fees. The second-largest decrease was associated with an $8,820 reduction in foreign exchange fluctuation, which decreased from a $9,041 loss incurred during the three-month period ended February 28, 2023, to a $221 loss incurred during the three-month period ended February 29, 2024. Corporate communication fees decreased by $4,365 to $635, and accounting and audit fees decreased by $574 to $6,426. These decreases were in part offset by increased professional fees of $16,124, which increased by $15,874, as compared to $250 incurred during the comparative three-month period ended February 28, 2023, and by $3,027 filing and regulatory fees, which increased by $591 from $2,436 for the comparative three-month period ended February 28, 2023. These fees increased as a result of debt conversion effected in December 2023, and changes to our corporate and capital structure during the third quarter of our Fiscal 2024.
Consulting fees increased by $21,051, from $14,274 for the three-month period ended February 28, 2023, to $35,325 incurred during the three months ended February 29, 2024.
On a year-to-date basis, operating expenses decreased by 60.6% from $383,839 incurred during the nine months ended February 28, 2023, to $151,391 incurred during the nine months ended February 29, 2024. The most significant changes were as follows:
·During the nine-month period ended February 29, 2024, consulting fees increased by $33,590, or 54.9%, from $61,206 incurred during the nine-month period ended February 28, 2023, to $94,796 incurred during the nine-month period ended February 29, 2024.
·Research and development fees for the nine-month period ended February 29, 2024, decreased by $109,273, or 123.1%, from $88,796 incurred during the nine-month period ended February 28, 2023, to a recapture of $20,477 incurred during the nine-month period ended February 29, 2024. The lower research and development fees during the nine-month period ended February 29, 2024, were associated with the decision to suspend further development of the eBalance® devices due to lack of funding and unfavorable financial position, as well as reversal of certain fees that were billed during the Fiscal 2023, for which the services were not provided.
·General and administrative fees for the nine-month period ended February 29, 2024, decreased by $156,765, or 67%, from $233,837 incurred during the nine-month period ended February 28, 2023, to $77,072 incurred during the nine-month period ended February 29, 2024. The largest factor that contributed to this change was associated with a decrease in management fees of $82,500, to $15,000, as during the current period ended February 29, 2024, the fees paid to the Company’s CFO have been included in consulting fees, in addition, during the comparative period the Company accrued $75,000 payable to a former CEO, as compared to $15,000 accrued as payable to the Company’s new CEO in the current period. In addition, during the current period, the Company incurred $547 in foreign exchange gain as compared to $84,241 loss in foreign
4
exchange recorded for the comparative period ended February 28, 2023. The corporate communications fees decreased by $17,734 to $3,168. These decreases were in part offset by $1,108 increase to audit and accounting fees, and $28,120 increase in professional fees to $29,731, which resulted from the legal assistance in preparing submissions to the BCSC with request to revoke the CTO, debt conversion, and proposed changes to corporate and capital structure of the Company.
Other Items
During the three-month period ended February 29, 2024, the Company accrued $9,771 (February 28, 2023 - $12,329) in interest associated with the outstanding notes and vendor payables. During the nine-month period ended February 29, 2024, $53,655 (February 28, 2023 - $32,774) was accrued in interest associated with the outstanding notes and vendor payables.
On December 18, 2023, the Company entered into debt settlement agreements to convert an aggregate amount of $1,622,693 into shares of common stock at a price of $0.007 per share for an aggregate of 231,813,310 shares of common stock. Simultaneously with the conversion of debt into shares, certain debt holders agreed to waive the accrued interest on the principal amount due under the notes payable, which resulted in a $100,186 gain on forgiveness of debt for the three- and nine-month periods ended February 29, 2024. Furthermore, the Company discharged outstanding debt to specific vendors due to the balances exceeding the statute of limitations, which resulted in an additional gain on forgiveness of debt of $87,331. There were no similar transactions for the three- and nine-month periods ended February 28, 2023.
Liquidity and Capital Resources
Working Capital
| As at February 29, 2024 |
| As at May 31, 2023 |
| Percentage Increase/ (Decrease) | ||
Current assets | $ | 81,918 |
| $ | 103,270 |
| (20.7)% |
Current liabilities |
| 791,864 |
|
| 2,488,750 |
| (68.2)% |
Working capital deficit | $ | (709,946) |
| $ | (2,385,480) |
| (70.2)% |
As of February 29, 2024, the Company had a cash balance of $79,677, a working capital deficit of $709,946, and cash flows used in operations of $113,630 for the period then ended. During the nine-month period ended February 29, 2024, the Company funded its operations with funds borrowed under loan agreements which were entered into during the quarter ended May 31, 2023, and by an additional $20,000 borrowed in January of 2024. These loans accumulate interest at 10% per annum, compounded monthly, and are due on demand. In addition, the Company received $75,000 in subscriptions to units of its common stock, which were issued on the close of the non-brokered private placement financing on March 12, 2024.
The Company did not generate sufficient cash flows from its operating activities to satisfy its cash requirements for the nine-month period ended February 29, 2024. The amount of cash generated from the operations to date is significantly less than the Company’s current debt obligations. There is no assurance that the Company will be able to generate sufficient cash from operations to repay the amounts owing under the outstanding notes and advances payable, or to service other debt obligations. If the Company is unable to generate sufficient cash flow from operations to repay the amounts owing when due, it may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern.
5
Cash Flows
| Nine months ended | ||||
| February 29, 2024 |
| February 28, 2023 | ||
Cash flows used in operating activities | $ | (113,630) |
| $ | (246,585) |
Cash flows provided by financing activities |
| 95,000 |
|
| 229,987 |
Effects of foreign currency exchange on cash |
| 12 |
|
| (154) |
Net decrease in cash during the period | $ | (18,618) |
| $ | (16,752) |
Net Cash Used in Operating Activities
Net cash used in operating activities during the nine months ended February 29, 2024, was $113,630. This cash was primarily used to cover cash operating expenses of $151,422, which were represented by a net loss of $17,529 and increased by the non-cash items totaling $133,893, and to decrease accrued liabilities by $23,465. These uses of cash were offset by a $23,640 increase in amounts due to related parties, a $34,851 increase to accounts payable, and a $2,766 decrease in other current assets, which include GST receivable and prepaid expenses.
Net cash used in operating activities during the nine months ended February 28, 2023, was $246,585. This cash was primarily used to cover cash operating activities of $311,812, which were represented by a net loss of $415,659 reduced by the non-cash items totaling $103,847, and to decrease accounts payable and accrued liabilities by $15,459 and $5,193, respectively. These uses of cash were offset by $75,759 increase in amounts due to related parties, and $10,120 decrease to current assets which include GST receivable and prepaid expenses.
Non-cash transactions
During the nine-month period ended February 29, 2024, net loss was affected by the following expenses that did not have any impact on cash used in operations:
·$187,517 (February 28, 2023 - $Nil) in gain on forgiveness of debt associated with the debt settlement agreements signed on December 18, 2023, whereby certain debt holders agreed to waive the accrued interest on the principal amounts due under the notes payable, resulting in a $100,186 debt forgiveness. Furthermore, the Company discharged outstanding debt to specific vendors due to the balances exceeding the statute of limitations, resulting in an additional gain on forgiveness of debt of $87,331;
·$53,655 (February 28, 2023 - $32,775) in interest accrued on the outstanding notes and vendor payables;
·$31 in unrealized foreign exchange gain (February 28, 2023 - $71,072 loss), which resulted from fluctuations of the Canadian dollar, the functional currency of Cell MedX Canada, in relation to the US dollar, the functional currency of the parent company, being also the Company’s reporting currency;
Net Cash Used in Investing Activities
The Company did not have any investing activities during the nine-month periods ended February 29, 2024 and February 28, 2023.
Net Cash Provided by Financing Activities
During the nine-month period ended February 29, 2024, the Company received $10,000 from Mr. Vahabzadeh, the Company’s director, and an additional $10,000 from Mr. Ahdoot in exchange for notes payable due on demand and accumulating interest at 10% per annum. In addition, the Company received $75,000 in subscriptions to units of its common stock as part of the non-brokered private placement financing that was closed on March 12, 2024. Mr. Vahabzadeh and his spouse participated in the offering acquiring a total of 1,000,000 Units for $30,000.
During the nine-month period ended February 28, 2023, the Company received $137,372 under a number of loan agreements with Mr. Richard Jeffs, which were payable on demand and accumulated interest at 6% per annum. On October 12, 2022, the Company signed an agreement with Mr. Richard Jeffs to amend certain terms included in the loan agreements with him totaling $539,325. Under the amended terms, upon a default of any payment of the amount owed under the amended loan agreements, Mr. Richard Jeffs was to have full right and title of ownership to the eBalance® Technology and any and all products developed by the Company and its subsidiary based on the eBalance® Technology, as well as all eBalance® trademarks and certifications the Company was granted. All other
6
terms of the loan agreements, including repayment date and interest rate, remained substantially the same. In December of 2023 Mr. Richard Jeffs assigned a portion of his loans to Mr. David Jeffs, and on December 29, 2023, these loans were converted to the shares of the Company’s common stock, effectively removing Mr. Jeffs’ right and title of ownership to the eBalance® Technology as described earlier.
Going Concern
The notes to the Company’s unaudited condensed consolidated financial statements as at February 29, 2024, disclose an uncertain ability for the Company to continue as a going concern. The Company’s current business operations are in an early development stage and as such, its ability to generate revenue from the operations is very minimal. The Company's research and development as well as marketing plans require large capital expenditures. Due to the financial difficulties the Company faces, the research and development plans associated with the eBalance® technology were abandoned until such time that the Company has regained its financial stability. Management is planning to mitigate the Company’s shortfall in funds through equity or debt financing. On December 18, 2023, the Company entered into debt settlement agreements with its debt holders to convert $1,622,693 in current liabilities into 231,813,310 shares of common stock at a price of $0.007 per share, which resulted in a decrease to the working capital deficit. In addition, on March 12, 2024, the Company closed a non-brokered private placement financing for a total of 2,500,000 units at a price of $0.03 per Unit for gross proceeds of $75,000.
As at February 29, 2024, the Company had accumulated a deficit of $10,170,306 since inception and additional funding will be required to support the operations. The Company’s continuation as a going concern depends upon the continued financial support of its shareholders, its ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. The unaudited condensed consolidated interim financial statements do not give effect to any adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the Company’s financial statements.
Off-Balance Sheet Arrangements
None.
Critical Accounting Policies
An appreciation of the Company’s critical accounting policies is necessary to understand its financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact the financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. The Company has applied its critical accounting policies and estimation methods consistently.
Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure
None.
Item 3. Quantitative and Qualitative Disclosure about Market Risk
None
Item 4. Controls and Procedures
Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
7
An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of February 29, 2024. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.
During the quarter ended February 29, 2024, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
8
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
None.
Item 1A. Risk Factors
There is a high degree of risk associated with investing in our securities. Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.
The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results and common share value. The Company cannot assure that it will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment. The Company may encounter risks in addition to those described below. Additional risks and uncertainties not currently known, or that are currently deem to be immaterial, may also impair or adversely affect the Company’s business, financial condition or results of operation.
Risks Associated with the Company and Industry it Operates in
The Company operates in a highly competitive market. The Company faces competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treatment of pain and management of diabetes and related ailments. Many of these companies are very well accepted by health practitioners and have significant resources, and the Company may not be able to compete effectively.
The market for treatment and management of diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. The Company competes indirectly with pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, the MediSense Inc., and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate the Company’s target market they could threaten its position in the market.
The Company is subject to numerous governmental regulations which can increase its costs of developing the eBalance® Technology and products based on this technology.
The Company’s products are subject to rigorous regulation by the FDA, Health Canada and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals may not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, the Company’s products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In addition, no assurance can be given that the Company will remain in compliance with applicable FDA, Health Canada and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, advertising, and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.
Changes in the health care regulatory environment may adversely affect the Company’s business.
A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 and its amendments changed access to health care products and services and established new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. The Company cannot predict the timing or impact of any future rulemaking.
9
Inability to protect and enforce the Company’s intellectual property rights could adversely affect its financial results.
Intellectual property rights, including patents, trade secrets, confidential information, trademarks, tradenames, and other forms of trade dress, are important to the Company’s business. An inability to defend, protect and enforce its intellectual property rights could adversely affect the financial results, even if the Company is successful in developing and marketing products based on the eBalance® Technology. In addition, an adverse outcome in any litigation or interference proceeding could subject the Company to significant liabilities to third parties and require the Company to cease using the technology that is at issue or to license the technology from third parties. In addition, a finding that any of the Company’s intellectual property rights are invalid could allow the Company’s competitors to compete more easily and cost-effectively. Thus, an unfavorable outcome in any patent litigation or interference proceeding could have a material adverse effect on the Company’s business, financial condition, or results of operations.
The cost to the Company of any patent litigation or interference proceeding could be substantial. Uncertainties resulting from the initiation and continuation of patent litigation or interference proceedings could have a material adverse effect on the Company’s ability to compete in the marketplace. Patent litigation and interference proceedings could also absorb significant management time.
Competitors’ intellectual property may prevent the Company from selling its products or have a material adverse effect on its future profitability and financial condition.
Competitors may claim that the Company’s technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require the Company to enter into license agreements. The Company cannot guarantee that it would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject the Company to significant damages or an injunction preventing the manufacture, sale or use of its product. Any of these events could have a material adverse effect on the profitability and financial condition of the Company.
The Company’s research and development efforts may not result in the development of commercially successful products based on its eBalance® Technology, which may hinder its profitability and future growth.
The Company plans to continue to further research the eBalance® Technology and develop products based on the Technology. In order to develop commercially marketable products, the Company will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. The Company must make ongoing substantial expenditures without any assurance that its efforts will be commercially successful.
Failure can occur at any point in the process, including after significant funds have been invested. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.
Even if the Company successfully develops marketable products or commercially develop its current Technology, it may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors’ innovations.
Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. The Company cannot state with certainty when or whether its products under development will be launched, whether it will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause the Company’s products to become obsolete, causing its revenues and operating results to suffer.
New products and technological advances by the Company’s competitors may negatively affect its results of operations.
The Company’s products face intense competition from its competitors. Competitors’ products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than the
10
Company’s products. The Company cannot predict with certainty the timing or impact of the introduction of competitors’ products.
Significant safety concerns could arise for the Company’s products, which could have a material adverse effect on its revenues and financial condition.
Health care products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, the Company may be required to amend the conditions of use for a product. For example, the Company may be required to provide additional warnings on a product’s label or narrow its approved intended use, either of which could reduce the product’s market acceptance. If serious safety issues arise with its product, sales of the product could be halted by the Company or by regulatory authorities. Safety issues affecting suppliers’ or competitors’ products also may reduce the market acceptance of the Company’s products.
Inability to attract and maintain key personnel may cause the Company’s business to fail.
Success depends on the acquisition of key personnel. The Company will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants. If the Company cannot maintain qualified personnel to meet the needs of its anticipated growth, we could face material adverse effects on the Company’s business and financial condition.
The Company lacks operating history and to date has generated only minimal revenues. If the Company cannot increase its revenue to start generating profits, its investors may lose their entire investment.
To date, the Company has generated only minimal revenues. No profits have been made to date and if the Company fails to make any then it may fail as a business and an investment in its common stock will be worth nothing. The Company has a limited operating history and thus its progress as well as potential future success cannot be reasonably estimated. Success has yet to be proven and financial losses should be expected to continue in the near future and at least until such time that the Company enters commercial production of devices based on the eBalance® Technology, of which there is no assurance. As a new business, the Company faces all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties. Since inception, the Company has accumulated deficit of $10,170,306 and there is no guarantee, that it may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.
The Company needs to acquire additional financing, or its business will fail.
The Company must obtain additional capital, or its business will fail. In order to continue development of its eBalance® Technology, apply for medical licenses, FDA approvals, and to carry out its additional observational and clinical trials, the Company must secure more funds. Currently, the Company has limited resources and has already accumulated a deficit. The Company does not have immediate sources of financing. Financing may be subject to numerous factors including investor sentiment, acceptance of the Company’s technology and so on. The Company may also have to borrow large sums of money that require substantial capital and interest payments.
Risks related to the Company’s stock
The Company expects to raise additional capital through the offering of more shares, which will result in dilution to its current shareholders.
Raising additional capital through future offerings of common stock is expected to be necessary for the Company to continue. However, there is no guarantee that the Company will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of the Company’s shareholders.
The Company expects to convert some of the existing debt into shares of its common stock, which will result in dilution to its current shareholders.
In December 2023, the Company issued 231,813,310 shares of its common stock on conversion of a total of $1,622,693 in current liabilities, which resulted in a decrease to its working capital deficit. In order to reduce the
11
Company’s liabilities and improve its financial position further, the Company may continue converting its remaining debt to shares of common stock. Issuance of additional stock increases the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of the Company’s shareholders, further diluting their position.
Due to the current financial situation, and to improve likelihood of successful financing in the future the Company may decide to consolidated issued and outstanding shares of its common stock.
In order to improve the financial position, the Company may elect to consolidate its issued and outstanding shares of common stock. The effect of a share consolidation on the per share trading price of the Company’s common stock cannot be predicted with any certainty, and the history of share consolidations for other companies is varied, particularly since some investors may view a share consolidation negatively. It is possible that the per share trading price of the Company’s common stock after a share consolidation would not increase in the same proportion as the reduction in the number of the Company’s outstanding shares of common stock following the share consolidation or at all, and a share consolidation may not result in a per share trading price that would attract investors who do not trade in lower priced stocks. The Company cannot assure you that, if a share consolidation is implemented, its common stock will be more attractive to investors. If the Company implements a share consolidation, the per share trading price of its common stock may decrease due to factors unrelated to the share consolidation, including its future performance. If a share consolidation is consummated and the per share trading price of the Company’s common stock declines, the percentages decline as an absolute number and as a percentage of the Company’s overall market capitalization may be greater than would occur in the absence of a share consolidation.
A share consolidation may decrease the liquidity of the Company’s common stock and result in higher transaction costs. The liquidity of the Company’s common stock may be negatively impacted by a share consolidation, given the reduced number of shares that would be outstanding after the share consolidation, particularly if the per share trading price does not increase as a result of the share consolidation. In addition, if a share consolidation is implemented, it will increase the number of the Company’s stockholders who own “odd lots” of fewer than 100 shares of common stock. Brokerage commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares of common stock.
There is a limited market for the Company’s common stock meaning that its shareholders may not be able to resell their shares.
The Company’s common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove exceedingly difficult. Private sales are more difficult and often give lower than anticipated prices.
Should a larger public market develop for the Company’s stock, future sales of shares may negatively affect their market price.
Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations. Liquidity may be low despite there being a market, making it difficult to get a return on the investment. The price also depends on potential investor’s feelings regarding the results of the Company’s operations, the competition of other companies’ shares, its ability to generate future revenues, and market perception about future of microcurrent technologies.
Because the Company stock is a penny stock, stockholders will be more limited in their ability to sell their stock.
The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.
Because the Company’s securities constitute “penny stocks” within the meaning of the rules, the rules apply to the Company and to its securities. The rules may further affect the ability of owners of shares to sell the Company’s securities in any market that might develop for them. As long as the quotation price of the Company’s common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:
12
·contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;
·contains a description of the broker’s or dealer’s duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws;
·contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;
·contains a toll-free telephone number for inquiries on disciplinary actions;
·defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and
·contains such other information and is in such form, including language, type, size, and format, as the SEC shall require by rule or regulation.
The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for the Company’s stock.
The Company has not paid nor anticipates paying cash dividends on its common stock.
The Company has not declared any dividends on its common stock during the past two fiscal years or at any time in its history. The Nevada Revised Statutes (the “NRS”), provide certain limitations on the Company’s ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits the Company from declaring dividends where, after giving effect to the distribution of the dividend:
(a)the Company would not be able to pay its debts as they become due in the usual course of business; or
(b)except as may be allowed by the Company’s Articles of Incorporation, its total assets would be less than the sum of its total liabilities plus the amount that would be needed, if the Company was to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution.
The Company does not expect to declare any dividends in the foreseeable future as it expects to spend any funds legally available for the payment of dividends on the development of its business.
No assurance that forward-looking assessments will be realized.
The Company’s ability to accomplish its objectives and whether or not it is financially successful is dependent upon numerous factors, each of which could have a material effect on the results obtained. Some of these factors are in the discretion and control of management and others are beyond management’s control. The assumptions and hypotheses used in preparing any forward-looking assessments contained herein are considered reasonable by management. There can be no assurance, however, that any projections or assessments contained herein or otherwise made by management will be realized or achieved at any level.
FOR ALL OF THE AFORESAID REASONS AND OTHERS SET-FORTH AND NOT SET-FORTH HEREIN, AN INVESTMENT IN THE COMPANY’S SECURITIES INVOLVES A CERTAIN DEGREE OF RISK. ANY PERSON CONSIDERING TO INVEST IN THE COMPANY’S SECURITIES SHOULD BE AWARE OF THESE AND OTHER FACTORS SET-FORTH IN THIS REPORT AND IN THE OTHER REPORTS AND DOCUMENTS THAT THE COMPANY FILES FROM TIME TO TIME WITH THE SEC AND SHOULD CONSULT WITH HIS/HER LEGAL, TAX, AND FINANCIAL ADVISORS PRIOR TO MAKING AN INVESTMENT IN THE COMPANY’S SECURITIES. AN INVESTMENT IN THE COMPANY’S SECURITIES SHOULD ONLY BE ACQUIRED BY PERSONS WHO CAN AFFORD TO LOSE THEIR TOTAL INVESTMENT.
13
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
None.
14
Item 6. Exhibits
Exhibit |
|
|
Number |
| Description of Document |
| Articles of Incorporation (2) | |
| Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.(3) | |
| Articles of Merger - Cell MedX Corp. and Sports Asylum, Inc.(3) | |
| Bylaws (1) | |
| Specimen Stock Certificate (1) | |
| Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(4) | |
| First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(5) | |
| Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(6) | |
| Intellectual Property Royalty Agreement between Cell MedX Corp. and Brek Technologies Inc., dated for reference September 6, 2018.(7) | |
| Royalty Agreement between Cell MedX Corp. and Mr. Richard Norman Jeffs, dated for reference September 6, 2018.(7) | |
| Credit Line Agreement dated December 27, 2018, between Richard Norman Jeffs and Cell MedX Corp.(8) | |
| Distribution Agreement between Cell MedX Corp. and Live Current Media, Inc., dated for reference March 21, 2019. (9) | |
| Buyback agreement between Live Current Media Inc. and Cell MedX Corp., dated January 29, 2020.(10) | |
| Loan Agreement dated July 3, 2020, among Cell MedX Corp. and David Jeffs. (11) | |
| Loan Agreement and Note Payable dated November 30, 2020, among Cell MedX Corp. and Tradex Capital Corp.(11) | |
| Loan Agreement and Note Payable dated December 14, 2020, among Cell MedX (Canada) Corp. and Richard Jeffs.(12) | |
| Loan Agreement and Note Payable dated December 23, 2020, among Cell MedX (Canada) Corp. and Richard Jeffs.(12) | |
| Loan Agreement and Note Payable dated March 29, 2021, among Cell MedX (Canada) Corp. and Susan Jeffs.(13) | |
| Loan Agreement and Note Payable dated April 15, 2021, among Cell MedX Corp. and Richard Jeffs.(13) | |
| Loan Agreement and Note Payable dated May 18, 2021, among Cell MedX Corp. and Richard Jeffs.(13) | |
| Loan Agreement and Note Payable dated June 22, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs.(13) | |
| Loan Agreement and Note Payable dated October 7, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs.(14) | |
| Loan Agreement and Note Payable dated October 26, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (14) | |
| Loan Agreement and Note Payable dated November 24, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (14) | |
| Loan Agreement and Note Payable dated November 29, 2021, among Cell MedX Corp. and Bradley Hargreaves. (14) |
15
Exhibit |
|
|
Number |
| Description of Document |
| Loan Agreement and Note Payable dated December 30, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (15) | |
| Loan Agreement and Note Payable dated January 27, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (15) | |
| Loan Agreement and Note Payable dated February 24, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (15) | |
| Loan Agreement and Note Payable dated March 29, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (15) | |
| Loan Agreement and Note Payable dated April 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (17) | |
| Loan Agreement and Note Payable dated May 31, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (17) | |
| Loan Agreement and Note Payable dated June 27, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (17) | |
| Loan Agreement and Note Payable dated July 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (17) | |
| Loan Agreement and Note Payable dated October 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(16) | |
| Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (16) | |
| Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (16) | |
| Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX Corp. and Richard Jeffs. (16) | |
| Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX Corp. and Richard Jeffs. (16) | |
| Loan Agreement dated September 2, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(17) | |
| Loan Agreement dated September 6, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(17) | |
| Loan Agreement dated November 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(17) | |
| Loan Agreement dated November 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(17) | |
| Loan Agreement dated December 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(17) | |
| Loan Agreement dated January 24, 2023, among Cell MedX Corp. and David Jeffs.(17) | |
| Loan Agreement dated January 24, 2023, among Cell MedX Corp. and Amir Vahabzadeh.(17) | |
| Loan Agreement dated January 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(17) | |
| Loan Agreement dated April 11, 2023, among Cell MedX Corp. and Amir Vahabzadeh. (218) | |
| Loan Agreement dated April 25, 2023, among Cell MedX Corp. and David Jeffs. (18) | |
| Loan Agreement dated May 16, 2023, among Cell MedX Corp. and Amir Vahabzadeh. (19) | |
| Loan Agreement dated May 18, 2023, among Cell MedX Corp. and Sam Ahdoot.(19) | |
| Loan Agreement dated January 4, 2024, among Cell MedX Corp. and Amir Vahabzadeh. | |
| Loan Agreement dated January 4, 2024, among Cell MedX Corp. and Sam Ahdoot. |
16
Exhibit |
|
|
Number |
| Description of Document |
| Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
101 |
| The following materials from this Quarterly Report on Form 10-Q for the three- and nine-month periods ended February 29, 2024 and February 28, 2023 formatted in iXBRL (extensible Business Reporting Language): |
|
| (1) Unaudited Condensed Consolidated Balance Sheets at February 29, 2024 and as at May 31, 2023. |
|
| (2) Unaudited Condensed Consolidated Statements of Operations for the three- and nine-month periods ended February 29, 2024 and February 28, 2023. |
|
| (3) Unaudited Condensed Consolidated Statement of Stockholders’ Deficit as at February 29, 2024. |
|
| (4) Unaudited Condensed Consolidated Statements of Cash Flows for the and nine-month periods ended February 29, 2024, and February 28, 2023. |
(1)Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC on July 13, 2010
(2)Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010
(3)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014
(4)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014
(5)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014
(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18, 2014
(7)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2018
(8)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2018
(9)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 27, 2019
(10)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 31, 2020
(11)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 15, 2020
(12)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 9, 2021
(13)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on August 30, 2021
(14)Filed as an exhibit to the Company’s Annual Report on Form 10-Q filed with the SEC on January 12, 2022
(15)Filed as an exhibit to the Company’s Annual Report on Form 10-Q filed with the SEC on April 14, 2022
(16)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 18, 2022
(17)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on April 7, 2023
(18)Filed as an exhibit to the Company’s Annual Report on Form 10-Q filed with the SEC on May 19, 2023
(19)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on June 29, 2023
17
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Cell MedX Corp. | |
|
| |
Date: April 15, 2024 | By: | /s/ David Jeffs |
|
| David Jeffs |
|
| Chief Executive Officer and Director |
|
| (Principal Executive Officer) |
|
|
|
|
|
|
Date: April 15, 2024 | By: | /s/Yanika Silina |
|
| Yanika Silina |
|
| Chief Financial Officer and Director |
|
| (Principal Accounting Officer) |
18
LOAN AGREEMENT
THIS LOAN AGREEMENT (the “Agreement”) dated this 4th day of January, 2024
BETWEEN:
Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada
(the “Lender”)
OF THE FIRST PART
AND
Cell MedX Corp. of 820 - 1130 Pender Street, West, Vancouver, BC V6E 4A4 Canada
(the “Borrower”)
OF THE SECOND PART
IN CONSIDERATION OF the Lender loaning certain monies (the “Loan”) to the Borrower, and the Borrower repaying the Loan to the Lender, both parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:
Loan Amount & Interest
The Lender promises to lend fifty thousand ($10,000) USD (the “Principal Amount”), to the Borrower and the Borrower promises to repay this Principal Amount to the Lender, at such address as may be provided in writing, with interest calculated and compounded monthly on the unpaid Principal Amount at the rate of 10.0% per annum.
Payment
This Loan is payable on demand. At any time while not in default under this Agreement, the Borrower may pay the outstanding balance then owing under this Agreement to the Lender without further bonus or penalty.
Default
Notwithstanding anything to the contrary in this Agreement, if the Borrower defaults in the performance of any obligation under this Agreement, then the Lender may declare the Principal Amount owing and interest due under this Agreement at that time to be immediately due and payable.
Governing Law
This Agreement will be construed in accordance with and governed by the laws of the Province of British Columbia.
Costs
All costs, expenses and expenditures including, without limitation, the complete legal costs incurred by enforcing this Agreement as a result of any default by the Borrower, will be added to the Principal Amount then outstanding and any accrued interest thereon, and will immediately be paid by the Borrower.
Binding Effect
This Agreement will pass to the benefit of and be binding upon the respective heirs, executors, administrators, successors and permitted assigns of the Lender. The Borrower waives presentment for payment, notice of non-payment, protest, and notice of protest.
Amendments
This Agreement may only be amended or modified by a written instrument executed by both the Borrower and the Lender.
Severability
The clauses and paragraphs contained in this Agreement are intended to be read and construed independently of each other. If any term, covenant, condition or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, it is the parties’ intent that such provision be reduced in scope by the court only to the extent deemed necessary by that court to render the provision reasonable and enforceable and the remainder of the provisions of this Agreement will in no way be affected, impaired or invalidated as a result.
General Provisions
Headings are inserted for the convenience of the parties only and are not to be considered when interpreting this Agreement. Words in the singular mean and include the plural and vice versa. Words in the masculine mean and include the feminine and vice versa.
Entire Agreement
This Agreement constitutes the entire agreement between the parties and there are no further items or provisions, either oral or otherwise.
IN WITNESS WHEREOF, the parties have duly affixed their signatures under hand and seal on this 4th day of January, 2024.
| Cell MedX Corp. | |
/s/ Amir Vahabzadeh |
| /s/ David Jeffs |
Amir Vahabzadeh |
| By: David Jeffs, CEO |
LOAN AGREEMENT
THIS LOAN AGREEMENT (the “Agreement”) dated this 4th day of January, 2024
BETWEEN:
Sam Ahdoot of 13077 Bluff Creek Drive, Playa Vista, CA, 90094, USA
(the “Lender”)
OF THE FIRST PART
AND
Cell MedX Corp. of 820 - 1130 Pender Street, West, Vancouver, BC V6E 4A4 Canada
(the “Borrower”)
OF THE SECOND PART
IN CONSIDERATION OF the Lender loaning certain monies (the “Loan”) to the Borrower, and the Borrower repaying the Loan to the Lender, both parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:
Loan Amount & Interest
The Lender promises to lend fifty thousand ($10,000) USD (the “Principal Amount”), to the Borrower and the Borrower promises to repay this Principal Amount to the Lender, at such address as may be provided in writing, with interest calculated and compounded monthly on the unpaid Principal Amount at the rate of 10.0% per annum.
Payment
This Loan is payable on demand. At any time while not in default under this Agreement, the Borrower may pay the outstanding balance then owing under this Agreement to the Lender without further bonus or penalty.
Default
Notwithstanding anything to the contrary in this Agreement, if the Borrower defaults in the performance of any obligation under this Agreement, then the Lender may declare the Principal Amount owing and interest due under this Agreement at that time to be immediately due and payable.
Governing Law
This Agreement will be construed in accordance with and governed by the laws of the Province of British Columbia.
Costs
All costs, expenses and expenditures including, without limitation, the complete legal costs incurred by enforcing this Agreement as a result of any default by the Borrower, will be added to the Principal Amount then outstanding and any accrued interest thereon, and will immediately be paid by the Borrower.
Binding Effect
This Agreement will pass to the benefit of and be binding upon the respective heirs, executors, administrators, successors and permitted assigns of the Lender. The Borrower waives presentment for payment, notice of non-payment, protest, and notice of protest.
Amendments
This Agreement may only be amended or modified by a written instrument executed by both the Borrower and the Lender.
Severability
The clauses and paragraphs contained in this Agreement are intended to be read and construed independently of each other. If any term, covenant, condition or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, it is the parties’ intent that such provision be reduced in scope by the court only to the extent deemed necessary by that court to render the provision reasonable and enforceable and the remainder of the provisions of this Agreement will in no way be affected, impaired or invalidated as a result.
General Provisions
Headings are inserted for the convenience of the parties only and are not to be considered when interpreting this Agreement. Words in the singular mean and include the plural and vice versa. Words in the masculine mean and include the feminine and vice versa.
Entire Agreement
This Agreement constitutes the entire agreement between the parties and there are no further items or provisions, either oral or otherwise.
IN WITNESS WHEREOF, the parties have duly affixed their signatures under hand and seal on this 4th day of January, 2024.
| Cell MedX Corp. | |
/s/ Sam Ahdoot |
| /s/ Joao (John) da Costa |
Sam Ahdoot |
| By: Joao (John) da Costa, COO |
CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, David Jeffs, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the period ending February 29, 2024, of Cell MedX Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 15, 2024
/s/ David Jeffs
David Jeffs
Chief Executive Officer
(Principal Executive Officer)
CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Yanika Silina, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the period ending February 29, 2024, of Cell MedX Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 15, 2024
/s/ Yanika Silina
Yanika Silina
Chief Financial Officer
(Principal Accounting Officer)
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending February 29, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: April 15, 2024
/s/ David Jeffs
David Jeffs
Chief Executive Officer
(Principal Executive Officer)
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending February 29, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: April 15, 2024
/s/ Yanika Silina
Yanika Silina
Chief Financial Officer
(Principal Accounting Officer)